An interventional study of Computer assisted ambulatory electroencephalogram in Early Onset Alzheimer Disease, sponsored by Mayo Clinic. Active, not recruiting at 1 site in United States. Open to participants aged 40 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-03-05.
Sponsored by Mayo Clinic · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Alzheimer Disease by Mayo Clinic — 8 open to participants now, 10 under way, none of them phase 3. Alzheimer Disease · Mayo Clinic.
Among the 21 studies in Alzheimer Disease by Mayo Clinic, this one is the 14th largest by planned enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2020, is one of 8 with no phase, and was the 11th registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →8 of the 21 studies in Alzheimer Disease by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 50–95 · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 18+ · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 60+ · Women only · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 21–80
Mayo Clinic · Sites in United States
Ages 50–90
By country, each count listing its studies:
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 40 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 4 · Phase 4 2
First in 2005; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 57 across the 17 interventional studies, 195 across the 4 observational. Of the 10 that completed or were terminated, 2 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
Mayo Clinic is the lead sponsor of 3,272 studies on the registry; 672 are open to participants now.
Of its 452 completed or terminated interventional studies of FDA-regulated products, 322 (71%) have results posted.
7 of the studies in Alzheimer Disease by Mayo Clinic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04785300Mayo ClinicALSENLITE: Senolytics for Alzheimer's Disease | 2026-12 |
| NCT04002583Mayo Clinic48-hour Ambulatory EEG Monitoring in Early Onset Alzheimer's Disease | 2026-12 |
| NCT04099823Mayo ClinicMR Evaluation of Cerebrospinal Fluid (CSF) Dynamics | 2027-01 |
| NCT02740634Mayo ClinicMolecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study | 2027-03 |
| NCT00950430Mayo ClinicImaging of Brain Amyloid Plaques in the Aging Population | 2027-06 |
Add all 7 to your calendar (.ics) → With an account.
Among the 21 studies in Alzheimer Disease by Mayo Clinic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Researchers are trying to determine the frequency of seizures and epilepsy in patients with Early-onset Alzheimer's disease (EOAD) using a 48-hour computer assisted ambulatory electroencephalogram.
Inclusion criteria for EOAD patients will be recruited from the LEADS trial with the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects with mild cognitive impairment due to EOAD will undergo a 48 hour computer assisted ambulatory electroencephalogram
Diagnostic Test: Computer assisted ambulatory electroencephalogram
A portable 16 channel CAA-EEG is used to detect epileptiform abnormalities in a 48 hour ambulatory electroencephalogram (EEG)
Also known as: CAA-EEG
Electrographic seizures: Number of subjects with electrographic seizures
Number of subjects with electrographic seizures in 48 hours on computer assisted ambulatory EEG
Time frame: 48 hours
Plan to share: No
Started Feb 2020 (actual). Primary completion is estimated for Dec 2026, 82 months after the start.
Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 82 months is above that.
Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.